Practical Aspects of Radioligand Therapy in the Clinic VL

Methods for Preparation and Administration of Pluvicto™ (177Lu-PSMA-617) - Kendra Harris

Details
From the Tulane Cancer Center, Kendra Harris, a radiation oncologist explains the process of preparing for administering a dose of Pluvicto™ (177Lu-PSMA-617). Lutetium-177 received FDA approval as the first targeted radioligand therapy for the treatment of PSMA positive metastatic castration-resistant prostate cancer (mCRPC). Biographies: Kendra Harris, MD, MSc, Chair, Radiation Oncology, Associat...

Preparing for Treatment with 177Lu-PSMA-617 - Kendra Harris

Details
From the Tulane Cancer Center, Kendra Harris, Chair of Radiation Oncology explains the process of preparing for treatment of Pluvicto™ (177Lu-PSMA-617). Lutetium recently received FDA approval as the first targeted radioligand therapy for the treatment of PSMA positive metastatic castration-resistant prostate cancer (mCRPC). Biographies: Kendra Harris, MD, MSc, Chair, Radiation Oncology, Associate...

Administering Pluvicto™ - A Patient Shares His Treatment Experience of 177Lu-PSMA-617 - Kendra Harris and Phillip Koo

Details
From the Tulane Cancer Center, Kendra Harris Chair of Radiation Oncology demonstrates the process of administering a dose of Pluvicto™ (177Lu-PSMA-617). Phillip Koo meets with the patient in a brief post-dose administration discussion. Lutetium recently received FDA approval as the first targeted radioligand therapy for the treatment of PSMA positive metastatic castration-resistant prostate cancer...

Integration of Pluvicto™ (177Lu-PSMA-617) in Clinical Practice - Oliver Sartor and Kendra Harris

Details
Drs Oliver Sartor and Kendra Harris join Phillip Koo to discuss the clinical implications and integration of Pluvicto™ into clinical practice and offer guidance to clinicians looking to implement this therapy in their clinics. Pluvicto™ (177Lu-PSMA-617) is the first FDA-approved targeted radioligand therapy for the treatment of metastatic castration-resistant prostate cancer. Biographies: A. Olive...

Radiation Safety and the Integration of Pluvicto™ (177Lu-PSMA-617) in Treatment of mCRPC- Kendra Harris

Details
Chair of Radiation Oncology at Tulane University Cancer Center, Kendra Harris joins Phillip Koo to discuss radiation safety in regards to the recent approval of Pluvicto™, the first targeted radioligand therapy for the treatment of metastatic castration-resistant prostate cancer. Biographies: Kendra Harris, MD, MSc, Chair, Radiation Oncology, Associate Professor, Tulane Cancer Center, Tulane Unive...

Building a Sustainable Radioligand Treatment Clinic – Charlotte Manogue

Details
Phillip Koo and Charlotte Manogue, GU Program Manager at Tulane Cancer Center discuss aspects of transitioning from a clinical trial model into a sustainable treatment program for 177Lu-PSMA-617 for advanced prostate cancer at Tulane Cancer Center in New Orleans, Louisiana. Biographies: Charlotte Manogue, MPH, Senior Clinical Research Coordinator, Tulane Cancer Center, Tulane University School of...

Patient Management and Operationalizing Lutetium-177–PSMA-617 for Metastatic Castration Resistant Prostate Cancer in the Clinic – Charlotte Manogue and Oliver Sartor

Details
Oliver Sartor, Medical Director of the Tulane Cancer Center and co-PI on the Phase III VISION trial, and Charlotte Manogue, Senior Clinical Research Coordinator at Tulane Cancer Center join Phillip Koo in a discussion on identifying the patients and managing the patient care process for treatment with radioligand therapy in the clinic. Biographies: Oliver Sartor, MD, CE and Bernadine Laborde Profe...

Establishing A Theranostics Clinic for Advanced Prostate Cancer – Kendra Harris and Charlotte Manogue

Details
Phillip Koo, Kendra Harris, Chair of Radiation Oncology, and Charlotte Manogue, Senior Clinical Research Coordinator discuss the process for establishing a theranostics clinic from the regulatory processes and obtaining radioactive materials license (RML) to obtaining clearance through the radiation safety committee. Together they demystify the processes required to establish a radioligand treatme...

The Stakeholders in Operationalizing an Integrated PSMA Imaging and Therapies Clinic - Kendra Harris

Details
Kendra Harris, Chair of Radiation Oncology at the Tulane Cancer Center joins Phillip Koo discussing the process and stakeholders required for developing and implementing a theranostics program, where there is an integration of PSMA imaging and PSMA targeted treatment in the radiation oncology (or nuclear medicine) clinic. The Tulane Cancer Center has successfully implemented a radioligand therapy...
email news signup